Matthew Ronsheim
Corporate Officer/Principal bij ENTASIS THERAPEUTICS HOLDINGS INC.
Vermogen: 639 653 $ op 31-05-2024
Actieve functies van Matthew Ronsheim
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| ENTASIS THERAPEUTICS HOLDINGS INC. | Corporate Officer/Principal | 01-09-2020 | - |
Loopbaan van Matthew Ronsheim
Eerdere bekende functies van Matthew Ronsheim
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| ENANTA PHARMACEUTICALS, INC. | Directeur/Bestuurslid | 01-06-2016 | 01-08-2019 |
| Corporate Officer/Principal | 01-06-2016 | 01-08-2019 |
Opleiding van Matthew Ronsheim
| Southern Connecticut State University | Undergraduate Degree |
| University of New Hampshire | Doctorate Degree |
Statistieken
Internationaal
| Verenigde Staten | 5 |
Operationeel
| Corporate Officer/Principal | 2 |
| Undergraduate Degree | 1 |
| Doctorate Degree | 1 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| ENANTA PHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Entasis Therapeutics Holdings, Inc.
 Entasis Therapeutics Holdings, Inc. BiotechnologyHealth Technology Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA. | Health Technology |
- Beurs
- Insiders
- Matthew Ronsheim
- Ervaring
